All In Biotech

Drug Trial Radar · NCT02888106

Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

A Multicenter, Open-label, Randomised, Comparative, Parallel-Arm, Phase II Study to Assess Efficacy and Safety of Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Last checked: Nov 20, 2026Latest source record: Apr 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

90

Actual

Start

Apr 2016

Primary completion

Nov 22, 2019

Study completion Oct 30, 2020

Sponsor

Lead sponsor
Hepatera Ltd.Industry
Sponsor type
Industry
First posted
Sep 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomised, Comparative, Parallel-Arm Study to Assess Efficacy and Safety of Myrcludex B in Combination with Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients with Chronic Viral Hepatitis B with Delta-agent

Conditions

  • Chronic Viral Hepatitis B With Delta-agent

Interventions

  • Myrcludex BDrug

    Lyophilised powder for solution for subcutaneous injection

  • PEG IFN alfa-2aDrug

    solution for subcutaneous injection, once per week

  • TenofovirDrug

    Film-coated tablets, 300 mg, per os, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Negative HDV RNA by PCRTime frame: 72 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • State Budgetary educational institution of higher professional education "South Ural State Medical University" Ministry of healthcare

    Chelyabinsk, Russia

  • State Budgetary Institution of healthcare "Specialized Clinical Infectious Diseases Hospital" Ministry of Health

    Krasnodar, Russia

  • Moscow Regional Research and Clinical Institute

    Moscow, Russia

  • Federal Budget Institution of Science "Central Research Institute of Epidemiology" of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance

    Moscow, Russia

  • LLC "Clinic of Modern Medicine"

    Moscow, Russia

  • Medical Company "Gepatolog" LLC

    Samara, Russia

  • State Budgetary Institution of healthcare 'Stavropol regional clinical hospital'

    Stavropol, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.